Rituximab maintenance post-induction (PRIMA schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-RITUXIMAB |
|---|
| ID | REG-RITUXIMAB-MAINTENANCE-FL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-FL-2024 SRC-NCCN-BCELL-2025 |
Notes
PRIMA trial schedule (Salles 2011, Lancet): rituximab 375 mg/m² q8w × 2 years post-BR/R-CHOP induction. Median PFS extended ~3 years vs observation; OS impact unclear. PJP prophylaxis (cotrimoxazole) ≥6 mo after last dose; HBV reactivation surveillance throughout.
Used By
Indication
IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE- IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE